Post by Cytiva

More than 20 phage therapy clinical trials were underway in 2025.​ The question is no longer whether bacteriophages are therapeutically interesting. It's whether they can be manufactured consistently enough to reach more patients.​ That's the challenge being explored through PHOENIX – a collaboration between Biofactory Competence Center, CRISP - Centre de recherche et d’innovation en sciences pharmaceutiques cliniques CHUV and Cytiva, focused on developing scalable purification approaches for therapeutic bacteriophages.​ In this video, an ÄKTA flux s arrives at BCC, where it will support tangential flow filtration (TFF) steps within the project.​ It's an exciting example of academia, healthcare and industry working together to tackle some very real process development challenges.​

Video Content